Adding intra-arterial chemo to standard BCG therapy may reduce recurrence risk for patients with non–muscle-invasive bladder cancer. The study was published as a preprint and has not yet been peer reviewed.
First Look
Adding intra-arterial chemo to standard BCG therapy may reduce recurrence risk for patients with non–muscle-invasive bladder cancer. The study was published as a preprint and has not yet been peer reviewed.
First Look